Subscribe to Print Edition | Fri., August 01, 2008 Tamuz 29, 5768 | | Israel Time: 02:31 (EST+7) web haaretz.com   Back to Homepage Rosner's Domain Diplomacy Defense Jewish World Opinion National Print Edition Car Rental Books Haaretz Magazine Business Real Estate Easy Start Travel Week's End Anglo File

Markets in Brief Arcadi Gaydamak said yesterday that he personally guarantees that his holding company Ameris Holdings will meet its NIS 28.5 million payment to Gmul, within 30 days. Gmul said at the start of the week that it would be acting to collect the debt, which had been due on June 30. Ameris Holdings paid less than a fifth of the debt by that date. (Rotem Sella) The second quarter was challenging for the global community, yet Alvarion posted a 21% increase in year over year revenues to $69.7 million for the quarter. But the company spent heavily on R&D, as a strategy, leading to a loss of $0.8 million or 1 cent per share. In the parallel quarter it had netted $0.6 million. Cash flow was positive, though, at $0.9 million. (Shmuel Shuster) Advertisement Also yesterday, Teva launched divalproex sodium delayed-release tablets, which is the generic equivalent of Depakote Tablets, used to treat bipolar disorder, epilepsy, and migraine headaches. Teva is providing the drug in 125 mg strength, in bottles sizes of 100, and in 250 mg and 500 mg strengths, in bottle sizes of 100 and 500 tablets. (TheMarker) Teva Pharmaceutical Industries is investing up to $10.5 million more in CureTech, according to a company valuation of $46 million. Following the Teva investment, CureTech's parent company Clal Bio will be posting a NIS 13 million capital gain, and Teva's stake in CureTech will increase to 38% at full dilution. CureTech is working on a drug to treat colon cancer. It will be using the money to carry out clinical trials of CT011 on humans with colon cancer. The drug is presently being tested for lymphoma. (Yoram Gabison) Midroog yesterday reiterated an Aa2/Stable rating for Discount Investment Corp bonds, a cool NIS 4.8 billion worth (face value). The credit rating agency noted DI's record on bettering value and its high liquidity (deriving in no small part from dividends from star holdings such as Cellcom and Super-Sol). Discount Investment also owns shares in Koor Industries and Elron Electronic Industries. Yes, Midroog noticed that the risk environment in which the companies operate has intensified, both because the market value of its portfolio companies has shrunk badly, and also because Discount Investment's own financial ratios have worsened. But its core portfolio companies are doing beautifully, the agency says. (Michael Rochvarger) Web application security company Applicure has signed a one-year agreement for an unnamed but reportedly leading hosting services company in the U.S. to market its software. Applicure, which was founded in 2004, gets monthly royalties on each server sold with its product installed. News of the deal sent Applicure stock leaping like an ibex and closing 17.5% higher, on underwhelming turnover of NIS 188,000. Turnover in the stock ranges from nonexistent to around NIS 300,000 a day. (Yuval Maoz) Aladdin Knowledge Systems announced yesterday a definitive agreement to acquire Secure SafeWord, an enterprise gateway security company, from Secure Computing Corporation. Aladdin is paying about $65 million in cash, including acquisition costs. Secure SafeWord added $32 million to Secure Computing's revenue in 2007. (TheMarker) ClickSoftware has signed a contract with Deutsche Telekom's residential broadband service unit, selling it licenses to continue to use its ClickSchedule software. The Israeli company's mobile workforce management technology will be used to automate scheduling and route optimization for more than 25,000 workers in the field, ClickSoftware says. (TheMarker) Clal Finance Batucha notes that Teva Pharmaceutical Industries achieved record results in the second quarter of 2008: sales passed $2.8 billion, record sales of multiple sclerosis treatment Copaxone, amounting to $563 million, and net profit of $539 million or 65 cents per share. Lovely. And now for its next trick? OK, it's buying Barr for $7.5 billion, we all know that. Clal Finance is intrigued by Parkinson's drug Azilect, sales of which were a mere $42.5 million in the second quarter. But the analysts feel that it's going to be Teva's next blockbuster drug. Stay tuned. (TheMarker) Voice over Internet technology company AudioCodes reported yesterday an 18.7% year over year increase in second-quarter revenues to $45.7 million, on which it netted $1.6 million. AudioCodes repurchased 1.8 million of its ordinary shares during the second quarter of 2008 at a cost of $7.2 million. It also bought back shares in the first quarter. (TheMarker) Bookmark to del.icio.us   'Weeds' whacking The Showtime series has steered away from Jewish stereotypes - until now. Stepping stones Hizb ut-Tahrir, which calls for a worldwide Islamic state, marches through Gaza.

Read & React Olmert: I'll quit once new Kadima leader chosen Responses: 139 ANALYSIS / Crushed and battered, Olmert finally broke Responses: 53 Gideon Levy: Top IDF officer should be tried for mass killing, not petty ATV incident Responses: 131 Hamas' Christian convert: I've left a society that sanctifies terror Responses: 287 Abbas: I'll continue to work toward peace with any elected Israeli prime minister Responses: 58 More Headlines 20:56 Abbas: I'll work toward peace with any elected Israeli prime minister 01:40 Livni: All parties that support peace must unite under Kadima 22:47 Abbas orders release of Hamas men arrested in West Bank 02:30 Hezbollah threatens 'practical measures' against Israeli overflights 00:58 Students describe 'reign of terror' in Hebrew U.'s sociology department 01:36 ANALYSIS / Better reporting contributes to perceived climbing U.K. anti-Semitism 21:48 Obama helps U.S. woman fight Palestinian husband for their daughters 01:55 Kibbutz Kfar Giladi, relatives of fallen IDF troops come closer to ending dispute 01:43 War crimes suspect Radovan Karadzic appears at UN court 01:18 Gaydamak to be indicted for fraud and money laundering 12:59 Hamas' Christian convert: I've left a society that sanctifies terror 22:27 ANALYSIS / Ehud Olmert failed in war and failed in peace 16:36 Despite sanctions, German firm closes 100m euro deal with Iran 19:43 Watchdog group to court: Don't let state delay payment to Holocaust survivors 17:39 Israeli envoy to Croatia condemns Nazi war criminal's funeral Previous Editions Select Day 31 jul 30 jul 29 jul 28 jul 27 jul 25 jul 24 jul 23 jul 22 jul 21 jul 20 jul 18 jul

Special Offers Advertisement Fattal Hotel Chain Perfectly located hotels on best resorts of Israel. MBA in Israel in English APPLY NOW! Limited spaces available Israel's Premier Real Estate Website www. israel-property.com Yossi Avrahami Presents: New Luxurious Projects in North Tel Aviv & Eilat Your vacation starts here Israel Travel Center Guaranteed Lowest Rates Hebrew Summer courses From $39.95 ISRAEL BONDS Build Israel Israel bonds - a multi-purpose way to celebrate Israel's 60th Eldan Rent a Car Israel's leading car rental company offers you a 20% discount on all online reservations Junkyard Junk a car - get free towing nationwide and a tax-deductible receipt

Home | TV | Print Edition | Diplomacy | Opinion | Arts & Leisure | Sports | Jewish World | Underground | Site rules |

Real Estate in Israel | Travel to Israel with Haaretz | Hotels Israel | Restaurants Israel | Tourist attractions Israel | Shops Israel

birthright Israel | Search engine marketing

Haaretz.com, the online edition of Haaretz Newspaper in Israel, offers real-time breaking news, opinions and analysis from Israel and the Middle East. Haaretz.com provides extensive and in-depth coverage of Israel, the Jewish World and the Middle East, including defense, diplomacy, the Arab-Israeli conflict, the peace process, Israeli politics, Jerusalem affairs, international relations, Iran, Iraq, Syria, Lebanon, the Palestinian Authority, the West Bank and the Gaza Strip, the Israeli business world and Jewish life in Israel and the Diaspora.

© Copyright  Haaretz. All rights reserved